| __timestamp | BioMarin Pharmaceutical Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 125883000 |
| Thursday, January 1, 2015 | 152008000 | 69036000 |
| Friday, January 1, 2016 | 209620000 | 72700000 |
| Sunday, January 1, 2017 | 241786000 | 105700000 |
| Monday, January 1, 2018 | 315264000 | 198700000 |
| Tuesday, January 1, 2019 | 359466000 | 117600000 |
| Wednesday, January 1, 2020 | 524272000 | 108100000 |
| Friday, January 1, 2021 | 470515000 | 122500000 |
| Saturday, January 1, 2022 | 483669000 | 146700000 |
| Sunday, January 1, 2023 | 577065000 | 257500000 |
| Monday, January 1, 2024 | 580235000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, BioMarin's cost of revenue surged by approximately 345%, peaking in 2023, while United Therapeutics saw a more modest increase of around 105%.
Understanding these trends provides valuable insights into each company's operational strategies and market positioning. As the biotech industry evolves, monitoring such financial metrics will be crucial for stakeholders and investors.
Cost of Revenue Trends: Novartis AG vs BioMarin Pharmaceutical Inc.
Cost Insights: Breaking Down Amgen Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and United Therapeutics Corporation's Expenses
Cost of Revenue: Key Insights for United Therapeutics Corporation and Walgreens Boots Alliance, Inc.
United Therapeutics Corporation vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Breaking Down SG&A Expenses: United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Analyzing Cost of Revenue: United Therapeutics Corporation and Wave Life Sciences Ltd.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc.